- 中文名称
ATXN7 一抗
- 英文名字
- ATXN7 Primary antibody
- 供应商
- Promab
- 产品货号
- PMB-P31716
- 产品报价
- ¥询价/100ul

- 产品说明书
- 点击查看
- 购买方式
- Promab中国区现货中心已经建立,95%产品中国有现货库存。银行转账、电汇、支票、现金,在线支付宝及网银支付,或直接与我们电话联系。本公司所有产品仅供科研使用,不用于临床诊断。
- 产品新闻

- 背景资料
- The autosomal dominant cerebellar ataxias (ADCA) are anheterogeneous group of neurodegenerative disorders characterized bynprogressive degeneration of the cerebellum, brain stem and spinalncord. Clinically, ADCA has been divided into three groups: ADCAntypes I-III. ADCAI is genetically heterogeneous, with five geneticnloci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6,nbeing assigned to five different chromosomes. ADCAII, which alwaysnpresents with retinal degeneration (SCA7), and ADCAIII oftennreferred to as the 'pure' cerebellar syndrome (SCA5), are mostnlikely homogeneous disorders. Several SCA genes have been clonednand shown to contain CAG repeats in their coding regions. ADCA isncaused by the expansion of the CAG repeats, producing an elongatednpolyglutamine tract in the corresponding protein. The expandednrepeats are variable in size and unstable, usually increasing innsize when transmitted to successive generations. This locus hasnbeen mapped to chromosome 3, and it has been determined that thendiseased allele associated with spinocerebellar ataxia-7 containsn38-130 CAG repeats (near the N-terminus), compared to 7-17 in thennormal allele. The encoded protein is a component of thenSPT3/TAF9/GCN5 acetyltransferase (STAGA) and TBP-freenTAF-containing (TFTC) chromatin remodeling complexes, and it thusnplays a role in transcriptional regulation. Alternative splicingnresults in multiple transcript variants.
- 应用类型
- WB
- 免疫原
- This ATXN7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 354-381 amino acids from the Central region of human ATXN7.
- 来源宿主
- Rabbit
- 反应性
- Human
- 保存建议
- 4℃短期保存;-20℃长期保存。避免冻融循环。
- 其他
- ProMab 生物技术公司通过整合生物信息学、分子生物学、蛋白质表达、纯化技术、基因克隆、微生物学和免疫学,利用新型高通量技术开发重组蛋白、抗体和工程细胞系并将其商业化。专注于免疫治疗领域,特别是 CAR-T/NK 细胞技术。ProMab 还开发了一种新型的 mRNA 脂质纳米颗粒(mRNA-LNP)平台,用于即用型试剂和定制研究服务,以推进现有产品并扩展到更多的研究领域。

- 注意
-
该页面的中文产品信息的翻译,仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前,请浏览说明书确认。
-